Skip to content

Origins of this Project

Rebecka Isaksson edited this page Jun 3, 2024 · 2 revisions

The Structural Genomics Consortium (SGC) is collaborating with the Rapidly Emerging Antiviral Drug Development Initiative (READDI) to identify orally-available small molecular drugs that can treat and prevent viral infections. The collaboration is funded by the National Institute of Health (NIH) through the READDI-AViDD project, specifically focused on viruses with potential for large global negative impact.

The collaboration is driven by identification and isolation of viral target proteins, and establishing assays to conduct high-throughput screening of various commercial and non-commercial libraries. The aim is to identify hits that can act as starting points for further medicinal chemistry development, that can eventually lead to new drugs we can use to combat viral infections that have potential to spread widely globally. All generated data is available online and updated regularly.

One promising protein target is the Dengue virus RNA-dependent RNA polymerase (DENV Rdrp).